Eyler
08/644289

FILE 'REGISTRY' ENTERED AT 15:48:13 ON 24 JUN 1999
L12 1 S SLRPFKALVREKGHRPSHSC/SQSP

=> d .bevreg1

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1999 ACS
RN 173787-20-7 REGISTRY
CN L-Cysteine, L-seryl-L-leucyl-L-arginyl-L-prolyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-L-arginyl-L-.alpha.-glutamyl-L-lysylglycyl-L-histidyl-L-arginyl-L-prolyl-L-seryl-L-histidyl-L-seryl- (9CI) (CA INDEX NAME)
SQL 20

SEQ 1 SLRPFKALVR EKGHRPSHSC
========== ==========
HITS AT: 1-20

REFERENCE 1: 128:216370

REFERENCE 2: 128:21873

REFERENCE 3: 124:173450

(FILE 'CAPLUS' ENTERED AT 15:49:12 ON 24 JUN 1999)
L13 3 S L12

=> d 1-3 .bevstr

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1998:178120 CAPLUS
DOCUMENT NUMBER: 128:216370
TITLE: Recombinant p53as protein and antibody for diagnosis and therapy of malignancy
INVENTOR(S): Kulesz-Martin, Molly F.
PATENT ASSIGNEE(S): Health Research, Inc., USA
SOURCE: U.S., 30 pp. Cont.-in-part of U.S. Ser. No. 259,612.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5726024	A	19980310	US 96-644291	19960510
US 5688918	A	19971118	US 94-259612	19940614
EP 806478	A2	19971112	EP 97-107696	19970512
EP 806478	A3	19990609		

Searcher : Shears 308-4994

R: BE, CH, DE, DK, FR, GB, LI, NL, SE

PRIORITY APPLN. INFO.:

US 93-100496	19930802
US 94-195952	19940211
US 94-259612	19940614
US 96-644289	19960510
US 96-644291	19960510
US 96-644456	19960510

AB The invention comprises plasmids and viral vectors contg. an animal p53as (alternatively spliced p53) cDNA sequence. A portion of the p53as sequence may be identified to a position of wild type p53 gene from the same animal. In preferred embodiments, the p53as is mouse or human p53as. A preferred viral vector is baculovirus vector. The invention further includes antibodies both polyclonal and monoclonal, to p53as and to at least a portion of human p53 intron 10 sequence encoding SLRPFKALVREKGHRPSSHSC, which is related to p53as sequences and plasmids and viral vectors contg. such sequences. All of the above find utility in studying p53 and p53as and their relative expressions which is believed important for detection and control of malignant cells and their susceptibility to treatment agents. The antibodies can detect the presence of p53as and related sequences and when injected into cells could cause cell cycle arrest and the plasmids and viral vectors, with appropriate promoters, can cause expression of the p53as and p53 intron 10 sequences which can affect cell growth and perhaps arrest certain malignancies.

IT **173787-20-7**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(recombinant p53as protein and antibody for diagnosis and therapy of malignancy)

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1997:761610 CAPLUS
DOCUMENT NUMBER: 128:21873
TITLE: P53as protein and antibody therefor
INVENTOR(S): Kulesz-Martin, Molly F.
PATENT ASSIGNEE(S): Health Research, Inc., USA
SOURCE: U.S., 25 pp. Cont.-in-part of U.S. Ser. No. 195,952.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5688918	A	19971118	US 94-259612	19940614
EP 652232	A1	19950510	EP 94-610042	19940801

Searcher : Shears 308-4994

R: BE, CH, DE, DK, FR, GB, LI, NL, SE				
JP 08099998	A2	19960416	JP 94-181558	19940802
CA 2150994	AA	19951215	CA 95-2150994	19950605
JP 08081500	A2	19960326	JP 95-169323	19950613
EP 709397	A1	19960501	EP 95-610034	19950614
R: BE, CH, DE, DK, FR, GB, LI, NL, SE				
US 5726024	A	19980310	US 96-644291	19960510
PRIORITY APPLN. INFO.:			US 93-100496	19930802
			US 94-195952	19940211
			US 94-259612	19940614

AB The invention comprises plasmids and viral vectors contg. an animal p53as cDNA sequence. A portion of the p53as sequence may be identified to a position of wild type p53 gene from the same animal. In preferred embodiments, the p53as is mouse or human p53as. A preferred viral vector is baculovirus vector. The invention further includes antibodies both polyclonal and monoclonal, to p53as and to at least a portion of human p53 intron 10 sequence encoding SLRPFKALVREKGHRPSSHSC which is related to p53as sequences and plasmids and viral vectors contg. such sequences. All of the above find utility in studying p53 and p53as and their relative expressions which is believed important for detection and control of malignant cells and their susceptibility to treatment agents. The antibodies can detect the presence of p53as and related sequences and when injected into cells could cause cell cycle arrest and the plasmids and viral vectors, with appropriate promotors, can cause expression of the p53as and p53 intron 10 sequences which can affect cell growth and perhaps arrest certain malignancies.

IT **173787-20-7**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(recombinant p53as protein and antibody for diagnosis and therapy of malignancy)

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER:	1996:126792 CAPLUS
DOCUMENT NUMBER:	124:173450
TITLE:	Monoclonal and polyclonal antibody to alternatively spliced p53 protein (p53as) for diagnosis and prognosis of cancer
INVENTOR(S):	Kulesz-Martin, Molly F.
PATENT ASSIGNEE(S):	Health Research, Inc., USA
SOURCE:	Can. Pat. Appl., 40 pp. CODEN: CPXXEB
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	6
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

CA 2150994	AA	19951215	CA 95-2150994	19950605
US 5688918	A	19971118	US 94-259612	19940614
PRIORITY APPLN. INFO.:			US 94-259612	19940614
			US 93-100496	19930802
			US 94-195952	19940211

AB The invention comprises plasmids and viral vectors contg. an animal p53as cDNA sequence. A portion of the p53 sequence may be identified to a position of wild type p53 gene from the same animal. In preferred embodiments, the p53as is mouse or human p53as. A preferred viral vector is baculovirus vector. The invention further includes antibodies both polyclonal and monoclonal, to p53as and to at least a portion of human p53 intron 10 sequence encoding SLRPFKALVREKGHRPSHSC which is related to p53as sequences and plasmids and viral vectors contg. such sequences. All of the above find utility in studying p53 and p53as and their relative expressions which is believed important for detection and control of malignant cells and their susceptibility to treatment agents. The antibodies can detect the presence of p53as and related sequences and when injected into cells could cause cell cycle arrest and the plasmids and viral vectors, with appropriate promotors, can cause expression of the p53as and p53 intron 10 sequences which can affect cell growth and perhaps arrest certain malignancies.

IT **173787-20-7**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyclonal or monoclonal antibody to human or mouse p53as proteins for diagnosis or prognosis of cancer)

=> fil hom

FILE 'HOME' ENTERED AT 15:49:47 ON 24 JUN 1999

MPSRCH (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

```
MPsrch_pp   protein - protein database search, using Smith-Waterman algorithm

Run on:          Wed Jun 23 14:53:55 1999;  MasPar time 41.91 Seconds
                                            10.148 Million cell updates/sec
Tabular output not generated.

Title:           >US-08-644-289-1
Description:     (1-20) from US08644289.pep
Perfect Score:   151
Sequence:        1 SLRPFKALVREKGHRPSHSC 20

Scoring table:   PAM 150
                 Gap 15

Searched:        170751 seqs, 21266608 residues

Post-processing: Minimum Match 0%
                 Listing first 1000 summaries
                 Maximum DB seq length 30

Database:        a-geneseq35
                   1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7
                   8:part8 9:part9 10:part10 11:part11 12:part12 13:part13
                   14:part14 15:part15 16:part16 17:part17 18:part18
                   19:part19 20:part20 21:part21 22:part22 23:part23
                   24:part24 25:part25 26:part26 27:part27 28:part28
                   29:part29 30:part30 31:part31 32:part32 33:part33
                   34:part34 35:part35 36:part36 37:part37 38:part38
                   39:part39

Statistics:      Mean 20.743;  Variance 62.468;  scale 0.332
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description	Pred. No.
1	151	100.0	20	18	R92698	Human wild-type p53 g	5.67e-10
2	136	90.1	21	29	W33235	Human p53 fragment.	4.52e-08
3	85	56.3	20	29	W33239	Peptide of the human	7.01e-02
4	50	33.1	18	8	R44726	HEV ORF1 peptide (123	4.09e+02
5	48	31.8	17	29	W33236	Mouse p53as peptide.	6.37e+02
6	47	31.1	24	7	R37861	HIV protein fragment	7.92e+02
7	46	30.5	16	9	R45673	RNIP heparin binding	9.83e+02
8	46	30.5	20	26	W26230	pMA2-TH-IgG junction	9.83e+02
9	46	30.5	29	9	R45671	N terminus of human C	9.83e+02
10	45	29.8	14	6	R32978	Mastoparan analogue (	1.22e+03
11	45	29.8	19	24	W28500	Last 19 C-terminal am	1.22e+03
12	45	29.8	27	3	R11996	N-terminal of p29 pro	1.22e+03
13	44	29.1	15	21	W15386	N-alpha-Ac-[Ala26,Phe	1.50e+03
14	44	29.1	15	20	W12816	Peptide chain ENCFE6V	1.50e+03
15	44	29.1	15	33	W51822	Peptide YY analogue #	1.50e+03
16	44	29.1	15	12	R62078	Porcine PYY analogue	1.50e+03
17	44	29.1	15	20	W12817	Peptide chain ENCFE6V	1.50e+03
18	43	28.5	15	12	R62073	Porcine PYY analogue	1.85e+03
19	43	28.5	15	33	W51827	Peptide YY analogue #	1.85e+03
20	43	28.5	21	28	W47673	Antimicrobial peptide	1.85e+03
21	43	28.5	21	28	W47676	Antimicrobial peptide	1.85e+03
22	43	28.5	23	18	R92428	Lytic peptide used in	1.85e+03
23	43	28.5	23	18	R89985	Synthetic lytic pepti	1.85e+03
24	43	28.5	24	28	W47667	Antimicrobial peptide	1.85e+03
25	43	28.5	27	18	R92430	Lytic peptide used in	1.85e+03
26	43	28.5	27	18	R89987	Synthetic lytic pepti	1.85e+03
27	43	28.5	27	18	R92429	Lytic peptide used in	1.85e+03
28	43	28.5	28	28	W47653	Antimicrobial peptide	1.85e+03
29	43	28.5	28	28	W47652	Antimicrobial peptide	1.85e+03
30	43	28.5	28	28	W47651	Antimicrobial peptide	1.85e+03
31	43	28.5	28	28	W47654	Antimicrobial peptide	1.85e+03
32	43	28.5	28	28	W47655	Antimicrobial peptide	1.85e+03

Note: Post-processor removed 968 summaries from list due to search parameters chosen.

ALIGNMENTS

```
RESULT    1
ID   R92698 standard; peptide; 20 AA.
AC   R92698;
DT   03-OCT-1996  (first entry)
DE   Human wild-type p53 gene intron 10 encoded epitope.
KW   Tumour suppressor; p53; alternative splicing; antibody; cancer;
KW   proliferative disorder; psoriasis; prognosis; diagnosis; cell cycle.
OS   Homo sapiens.
PN   CA2150994-A.
PD   15-DEC-1995.
PF   05-JUN-1995; 150994.
PR   14-JUN-1994; US-259612.
PA   (HEAL-) HEALTH RES INC.
PI   Kulesz-Martin MF;
DR   WPI; 96-140137/15.
PT   New antibodies specific for alternatively spliced mammalian p53  -
PT   useful in diagnosis or prognosis of cancer, and for establishing
PT   individual treatment regimes.
PS   Claim 5; Page 25; 40pp; English.
CC   R92698 is an epitope from intron 10 of the human p53 gene. Antibodies
CC   directed against this sequence in an alternatively spliced p53 are
CC   useful in diagnosis and prognosis of human cancer. Antibodies against
CC   the epitope may be used in the study of p53 and alternatively spliced
CC   p53 (p53as) and their expression, when the antibodies are injected
CC   into cells they may cause cell cycle arrest. Vectors contg. p53as
CC   cDNA may be used in gene therapy of cancers and other proliferative
CC   disorders e.g. psoriasis.
SQ   Sequence   20 AA;

  Query Match            100.0%;  Score 151;  DB 18;  Length 20;
  Best Local Similarity 100.0%;  Pred. No. 5.67e-10;
  Matches    20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Db       1 slrpfkalvrekghrpshsc 20
           ||||||||||||||||||||
Qy       1 SLRPFKALVREKGHRPSHSC 20


RESULT    2
ID   W33235 standard; peptide; 21 AA.
AC   W33235;
DT   28-MAY-1998  (first entry)
DE   Human p53 fragment.
KW   Human p53 protein; p53as protein; antigen; antibody; cell-growth;
KW   differentiation; cancer; G2 phase; gene therapy.
OS   Homo sapiens.
PN   EP-806478-A2.
PD   12-NOV-1997.
PF   12-MAY-1997; 107696.
PR   10-MAY-1996; US-644456.
```

```
PR   10-MAY-1996; US-644289.
PR   10-MAY-1996; US-644291.
PA   (HEAL-) HEALTH RES INC.
PI   Kulesz-Martin MF;
DR   WPI; 97-538617/50.
PT   Alternatively spliced synthetic p53 protein, p53as - useful to
PT   generate specific antibody for cell growth and differentiation
PT   research
PS   Disclosure; Page 3; 67pp; English.
CC   This peptide is a fragment of the human p53 protein.  It has at least
CC   80% homology with a novel p53as protein for mammals, and the same
CC   sequence specific binding on the cellular level as active p53 protein
CC   from that mammal, except that the sequence specific binding of the novel
CC   peptide remains active in cellular environments in which the sequence
CC   specific binding of p53 protein is deactivated.  The novel peptide
CC   differs from p53 protein in the final 50 carboxy-terminal amino acids of
CC   p53 protein, and contains a specific antigen site not present in p53
CC   protein, giving rise to an antibody unique for the p53as peptide.
CC   Antibodies specific for murine p53as protein can be used in cell growth
CC   and differentiation basic research.  The development of a homologous
CC   protein for use in human cells, would have applications in the diagnosis
CC   and prognosis of human diseases such as cancer, and in the design of
CC   treatment strategies for such diseases.  The association of p53as protein
CC   expression with the G2 phase of the cell cycle suggests a functional role
CC   in G2 arrest, and the potential use of the p53as coding sequence for gene
CC   therapy.
SQ   Sequence   21 AA;

  Query Match           90.1%;  Score 136;  DB 29;  Length 21;
  Best Local Similarity  95.2%;  Pred. No. 4.52e-08;
  Matches   20;  Conservative    0;  Mismatches   0;  Indels   1;  Gaps   1;

Db      1 slrpfkalvrekghrpsshsc 21
          |||||||||||||||| |||
Qy      1 SLRPFKALVREKGHRPS-HSC 20


RESULT    3
ID   W33239 standard; peptide; 20 AA.
AC   W33239;
DT   28-MAY-1998  (first entry)
DE   Peptide of the human p53as protein.
KW   Human p53as peptide; mouse p53 protein; antigen; antibody; cell growth;
KW   differentiation; cancer; G2 phase; gene therapy.
OS   Homo sapiens.
PN   EP-806478-A2.
PD   12-NOV-1997.
PF   12-MAY-1997; 107696.
PR   10-MAY-1996; US-644456.
PR   10-MAY-1996; US-644289.
PR   10-MAY-1996; US-644291.
PA   (HEAL-) HEALTH RES INC.
PI   Kulesz-martin MF;
DR   WPI; 97-538617/50.
PT   Alternatively spliced synthetic p53 protein, p53as - useful to
PT   generate specific antibody for cell growth and differentiation
PT   research
PS   Disclosure; Page 11; 67pp; English.
CC   This peptide is unique to human p53as, and is encoded by intron 10.  It
CC   was used to immunise rabbit in order to generate polyclonal antibodies
CC   to to mouse p53as.  The novel peptide (p53as) differs from p53 protein
CC   in the final 50 carboxy-terminal amino acids of p53 protein, and
CC   contains a specific antigen site not present in p53 protein, giving rise
CC   to an antibody unique for the p53as peptide.  Antibodies specific for
CC   murine p53as protein can be used in cell growth and differentiation basic
CC   research.  The development of a homologous protein for use in human
CC   cells, would have applications in the diagnosis and prognosis of human
CC   diseases such as cancer, and in the design of treatment strategies for
CC   such diseases.  The association of p53as protein expression with the G2
CC   phase of the cell cycle suggests a functional role in G2 arrest, and the
CC   potential use of the p53as coding sequence for gene therapy.
SQ   Sequence   20 AA;

  Query Match           56.3%;  Score 85;  DB 29;  Length 20;
  Best Local Similarity 100.0%;  Pred. No. 7.01e-02;
  Matches   11;  Conservative    0;  Mismatches   0;  Indels   0;  Gaps   0;

Db      1 rekghrpshsc 11
          ||||||||||||
Qy     10 REKGHRPSHSC 20


RESULT    4
ID   R44726 standard; peptide; 18 AA.
AC   R44726;
DT   11-JAN-1994  (first entry)
DE   HEV ORF1 peptide (1237-1254).
KW   Enterically transmitted non-A non-B hepatitis; ET-NANB;
KW   vaccine.
OS   Hepatitis E virus.
PN   WO9314116-A.
PD   22-JUL-1993.
PF   15-JAN-1993; U00459.
PR   17-JAN-1992; US-822335.
PR   01-MAY-1992; US-876941.
PA   (GENE-) GENELABS TECHNOLOGIES INC.
PA   (USSH ) US SEC DEPT HEALTH.
PI   Bradley DW,  Carl M,  Reyes GR,  Tam AW;
DR   WPI; 93-243144/30.
PT   New immunogenic hepatitis E virus (HEV) peptide(s) - are from the
PT   ORF1, ORF2 and ORF3 regions of HEV, useful as a vaccine against
PT   HEV infection
PS   Claim 1; Fig 11; 48pp; English.
CC   Immunogenic hepatitis E virus (HEV) peptides are selected from the
CC   ORF1, ORF2 and ORF3 regions of HEV.  The peptides can be used in
CC   vaccines to prevent infection by HEV.  The antibodies can neutralise
CC   and block HEV infection and can be used to prevent or treat HEV
CC   infection.  The peptides and antibodies can also be used as
CC   diagnostic reagents.
SQ   Sequence   18 AA;

  Query Match           33.1%;  Score 50;  DB 8;  Length 18;
  Best Local Similarity  46.7%;  Pred. No. 4.09e+02;
  Matches    7;  Conservative    2;  Mismatches   6;  Indels   0;  Gaps   0;

Db      3 isafhqlaeelghrp 17
          : :|  |  | ||||
Qy      2 LRPFKALVREKGHRP 16


RESULT    5
ID   W33236 standard; peptide; 17 AA.
AC   W33236;
DT   28-MAY-1998  (first entry)
DE   Mouse p53as peptide.
KW   Mouse p53as peptide; human p53 protein; antigen; antibody; cell growth;
KW   differentiation; cancer; G2 phase; gene therapy.
OS   Mus sp.
PN   EP-806478-A2.
PD   12-NOV-1997.
PF   12-MAY-1997; 107696.
PR   10-MAY-1996; US-644456.
PR   10-MAY-1996; US-644289.
PR   10-MAY-1996; US-644291.
PA   (HEAL-) HEALTH RES INC.
PI   Kulesz-Martin MF;
DR   WPI; 97-538617/50.
PT   Alternatively spliced synthetic p53 protein, p53as - useful to
PT   generate specific antibody for cell growth and differentiation
PT   research
PS   Disclosure; Page 7; 67pp; English.
CC   This is a peptide from an alternatively spliced mouse p53as gene.  It
CC   has at least 80% homology with a fragment of the human p35 protein, and
CC   the same sequence specific binding on the cellular level as active p53
CC   protein from that mammal, except that the sequence specific binding of
CC   the novel peptide remains active in cellular environments in which the
```

```
CC   sequence specific binding of p53 protein is deactivated.  The novel
CC   peptide differs from p53 protein in the final 50 carboxy-terminal amino
CC   acids of p53 protein, and contains a specific antigen site not present
CC   in p53 protein, giving rise to an antibody unique for the p53as peptide.
CC   Antibodies specific for murine p53as protein can be used in cell growth
CC   and differentiation basic research.  The development of a homologous
CC   protein for use in human cells, would have applications in the diagnosis
CC   and prognosis of human diseases such as cancer, and in the design of
CC   treatment strategies for such diseases.  The association of p53as protein
CC   expression with the G2 phase of the cell cycle suggests a functional role
CC   in G2 arrest, and the potential use of the p53as coding sequence for gene
CC   therapy.
SQ   Sequence   17 AA;

  Query Match           31.8%;  Score 48;  DB 29;  Length 17;
  Best Local Similarity  55.6%;  Pred. No. 6.37e+02;
  Matches     5;  Conservative    3;  Mismatches   1;  Indels   0;  Gaps   0;

Db      4 rafqalike 12
            |:| ||::|
Qy      3 RPFKALVRE 11


RESULT    6
ID   R37861 standard; peptide; 24 AA.
AC   R37861;
DT   21-OCT-1993  (first entry)
DE   HIV protein fragment vif-C(170-192).
KW   Human immunodeficiency virus; screening; detection; AIDS;
KW   acquired immune deficiency syndrome; viral infectivity.
OS   Synthetic.
FH   Key             Location/Qualifiers
FT   misc_difference 1
FT                   /note= "opt.absent"
PN   J05125096-A.
PD   21-MAY-1993.
PF   02-NOV-1991; 288159.
PR   02-NOV-1991; JP-288159.
PA   (YAWH ) NIPPON STEEL CHEM CO.
PA   (YAWA ) NIPPON STEEL CORP.
DR   WPI; 93-200512/25.
PT   New peptide(s) - useful for diagnosis of HIV infection
PS   Claim 1; Page 2; 11pp; Japanese.
CC   This peptide has a sequence corresponding to part of the HIV
CC   C-terminal region. It is useful as a diagnostic agent for screening
CC   and monitoring HIV carriers. See also R37860.
SQ   Sequence   24 AA;

  Query Match           31.1%;  Score 47;  DB 7;  Length 24;
  Best Local Similarity  60.0%;  Pred. No. 7.92e+02;
  Matches     6;  Conservative    2;  Mismatches   2;  Indels   0;  Gaps   0;

Db     11 ktkghrgsht 20
          : |||| ||:
Qy     10 REKGHRPSHS 19


RESULT    7
ID   R45673 standard; Protein; 16 AA.
AC   R45673;
DT   25-JUL-1994  (first entry)
DE   RNIP heparin binding fragment.
KW   Cationic antibacterial protein; lipopolysaccharide binding;
KW   anticoagulant; granulocytes; RNIP; LPS; sepsis; autoimmune disorder;
KW   septic shock; rabbit; CAP18.
OS   Synthetic.
PN   WO9402589-A.
PD   03-FEB-1994.
PF   15-JUL-1993; U06731.
PR   17-JUL-1992; US-916761.
PR   17-JUL-1992; US-916765.
PA   (PANO-) PANORAMA RES INC.
PI   Hirata M,  Larrick JW,  Wright SC;
DR   WPI; 94-048847/06.
PT   Sequences encoding mammalian cationic antibacterial proteins -
PT   are homologous to human and rabbit CAP18 sequences and have
PT   lipo:polysaccharide binding and anti-coagulation activity
PS   Disclosure; Page 50; 112pp; English.
CC   The sequence of CAP18 C-terminal RNIP was compared to that of a
CC   number of heparin binding proteins to determine residues important for
CC   binding to lipopolysaccharides and inhibiting LPS-mediated activation
CC   of macrophage, as well as interfering with the clotting cascade to
CC   inhibit coagulation in conditions of disseminated intravascular
CC   coagulation.
CC   See also R45667-81.
SQ   Sequence   16 AA;

  Query Match           30.5%;  Score 46;  DB 9;  Length 16;
  Best Local Similarity  45.5%;  Pred. No. 9.83e+02;
  Matches     5;  Conservative    3;  Mismatches   3;  Indels   0;  Gaps   0;

Db      6 lrkfrnkikek 16
            || |:  ::||
Qy      2 LRPFKALVREK 12


RESULT    8
ID   W26230 standard; peptide; 20 AA.
AC   W26230;
DT   16-MAR-1998  (first entry)
DE   pMA2-TH-IgG junction region of fusion proteins.
KW   Fusion protein; hydrophilic spacer; recombinant; expression system;
KW   carboxypeptidase.
OS   Synthetic.
PN   WO9728272-A1.
PD   07-AUG-1997.
PF   31-JAN-1997; U01470.
PR   31-JAN-1996; US-595043.
PA   (TECH-) TECHNOLOGENE INC.
PI   Sgarlato GD;
DR   WPI; 97-402624/37.
DR   N-PSDB; T80156.
PT   Recombinant protein expression system for fusion protein production
PT   - useful for high quantity production of authentic recombinant
PT   proteins
PS   Example 1; Fig 7; 194pp; English.
CC   A novel recombinant vector has been developed which comprises a
CC   nucleotide sequence encoding a fusion protein. The fusion protein
CC   comprises three domains joined together in order, from N-terminus to
CC   C-terminus, of a first domain comprising a protein of interest, a second
CC   domain comprising a hydrophilic spacer and an affinity domain, each
CC   domain comprising amino acid residues. The present sequence represents
CC   a junction region (i.e. the region which joins the protein of interest
CC   with the affinity domain) present in pMA2-TH-IgG, used in example 1
CC   of the present invention. The recombinant vector is used for the
CC   production of authentic recombinant proteins of interest. The method of
CC   the invention is useful for the expression of fusion proteins capable of
CC   isolation by affinity chromatography in pro- or eukaryotic cells. This
CC   method allows for the efficient cleavage and generation of authentic
CC   proteins of interest that do not contain extraneous (i.e. non-naturally
CC   occurring) amino acids.
SQ   Sequence   20 AA;

  Query Match           30.5%;  Score 46;  DB 26;  Length 20;
  Best Local Similarity  35.3%;  Pred. No. 9.83e+02;
  Matches     6;  Conservative    5;  Mismatches   5;  Indels   1;  Gaps   1;

Db      4 sfrrlvp-rgrrtcppc 19
          :|: ||  :|:|   :|
Qy      4 PFKALVREKGHRPSHSC 20


RESULT    9
ID   R45671 standard; Protein; 29 AA.
AC   R45671;
DT   25-JUL-1994  (first entry)
```

```
DE   N terminus of human CAP18.
KW   Cationic antibacterial protein; lipopolysaccharide binding;
KW   anticoagulant; granulocytes; RNIP; LPS; sepsis; autoimmune disorder;
KW   septic shock; rabbit.
OS   Homo sapiens.
FH   Key             Location/Qualifiers
FT   misc_difference 23
FT                   /label= Asp, Lys
FT   misc_difference 26
FT                   /label= Gln, Ile
FT   misc_difference 27
FT                   /label= Gly, Gln
PN   WO9402589-A.
PD   03-FEB-1994.
PF   15-JUL-1993; U06731.
PR   17-JUL-1992; US-916761.
PR   17-JUL-1992; US-916765.
PA   (PANO-) PANORAMA RES INC.
PI   Hirata M,  Larrick JW,  Wright SC;
DR   WPI; 94-048847/06.
PT   Sequences encoding mammalian cationic antibacterial proteins -
PT   are homologous to human and rabbit CAP18 sequences and have
PT   lipo:polysaccharide binding and anti-coagulation activity
PS   Disclosure; Page 59; 112pp; English.
CC   The sequence is that of a human cationic antibacterial protein CAP18
CC   N-terminal fragment obtd. from granulocytes as sequenced.  The
CC   sequence corresponds to the N-terminus of the C-terminal RNIP fragment
CC   of rabbit CAP18.The fragment is capable of binding to lipopolysaccharide
CC   and inhibiting LPS-mediated activation of macrophage, as well as
CC   interfering with the clotting cascade to inhibit coagulation in
CC   conditions of disseminated intravascular coagulation.  The polypeptides
CC   can also be used to attenuate, inhibit or prevent LPS-associated
CC   conditions, e.g. sepsis, autoimmune disorders, inflammation, etc.
CC   See also R45667-81.
SQ   Sequence   29 AA;

  Query Match           30.5%;  Score 46;  DB 9;  Length 29;
  Best Local Similarity  45.5%;  Pred. No. 9.83e+02;
  Matches    5;  Conservative    3;  Mismatches   3;  Indels   0;  Gaps   0;

Db      6 lrkfrnkikek 16
            || |:  ::||
Qy      2 LRPFKALVREK 12


RESULT   10
ID   R32978 standard; peptide; 14 AA.
AC   R32978;
DT   02-JUL-1993  (first entry)
DE   Mastoparan analogue (41) having G protein modulatory activity.
KW   Mastoparan; MP; cellular regulation; receptor-based analogue;
KW   G protein; guanine nucleotide binding regulatory protein;
KW   asthma; ulcer; cardiovascular; disease; allergy; Parkinsons's;
KW   small cell carcinoma; lung; glaucoma; respiratory tract congestion;
KW   inflammation.
OS   Synthetic.
PN   WO9303749-A.
PD   04-MAR-1993.
PF   14-AUG-1992; U06825.
PR   21-AUG-1991; US-748319.
PA   (TEXA ) UNIV TEXAS SYSTEM.
PI   Higashijima T,  Ross EM;
DR   WPI; 93-093715/11.
PT   New peptide(s) contg. mastoparan- or receptor-analogue region -
PT   uses as G protein modulators, for treating asthma, ulcers,
PT   cardiovascular disorders and Parkinson's disease
PS   Claim 43; Page 83; 96pp; English.
CC   The peptide is an example of a highly generic formula, and is
CC   represented as found in the disclosure of the specifiation.  The
CC   claimed peptide lacks the N-terminal IN amino acids.
CC   The peptide is capable of modulating G protein action in a cell.  It
CC   may therefore by used for treating diseases involving G proteins,
CC   e.g. asthma, ulcers, cardiovascular diseases, allergies, Parkinson's
CC   disease, small cell carcinoma of the lung, glaucoma, respiratory
CC   tract congestion or inflammation.
SQ   Sequence   14 AA;

  Query Match           29.8%;  Score 45;  DB 6;  Length 14;
  Best Local Similarity  50.0%;  Pred. No. 1.22e+03;
  Matches    5;  Conservative    4;  Mismatches   1;  Indels   0;  Gaps   0;

Db      2 nlralralar 11
          :||:::|| |
Qy      1 SLRPFKALVR 10


RESULT   11
ID   W28500 standard; Protein; 19 AA.
AC   W28500;
DT   18-NOV-1997  (first entry)
DE   Last 19 C-terminal amino acids of alternatively spliced murine p53.
KW   Leucine zipper domain; LZD; oligomerisation domain; mutant; mutein;
KW   substitution; replacement; anti-oncogene; hyperproliferation;
KW   cancer; restenosis; tumour suppression; apoptosis; AS p53; mouse.
OS   Mus musculus.
PN   WO9704092-A1.
PD   06-FEB-1997.
PF   17-JUL-1996; F01111.
PR   19-JUL-1995; FR-008729.
PA   (RHON ) RHONE POULENC RORER SA.
PI   Bracco L,  Conseiller E;
DR   WPI; 97-132633/12.
DR   N-PSDB; T86212.
PT   New p53 variants e.g. with oligomerisation domain replaced by
PT   leucine zipper - useful for treating hyper-proliferative disorders,
PT   esp. cancer and restenosis
PS   Example A; Page 29; 133pp; French.
CC   A claimed p53 variant consists of a fragment coding for amino
CC   acids 1-366 of human p53 protein, followed by a fragment coding for
CC   the last 19 C-terminal amino acids of the alternatively spliced (AS)
CC   form of murine p53 (i.e. the present sequence). The variant is a
CC   more active and more stable tumour suppressor and apoptosis-inducing
CC   agent than wild-type p53 and is active where the wild-type protein
CC   is not.
SQ   Sequence   19 AA;

  Query Match           29.8%;  Score 45;  DB 24;  Length 19;
  Best Local Similarity  55.6%;  Pred. No. 1.22e+03;
  Matches    5;  Conservative    3;  Mismatches   1;  Indels   0;  Gaps   0;

Db      6 rafqalmke 14
          |:| ||::|
Qy      3 RPFKALVRE 11


RESULT   12
ID   R11996 standard; peptide; 27 AA.
AC   R11996;
DT   26-JUL-1991  (first entry)
DE   N-terminal of p29 protein.
KW   Wegener's granulomatosis; monoclonal antibodies; autoantibodies;
KW   glomerulonephritis; serine protease; antigen.
OS   Homo sapiens.
PN   WO9106572-A.
PD   16-MAY-1991.
PF   29-OCT-1990; U06277.
PR   27-OCT-1989; US-428286.
PA   (GEHO-) GEN HOSPITAL CORP.
PI   Arnaout M, Mccluskey RT, Niles J;
DR   WPI; 91-164137/22.
PT   Purified P29 protein - used to detect auto-antibodies diagnostic
PT   for Wegener's granulomatosis and conditions associated with
PT   glomerulo nephritis
PS   Claim 1; Page 22; 33pp; English.
CC   The p29 protein is a 29 kD antigen which was prepd. by affinity
CC   purificn. from neutrophil acid extract, using 1E8 monoclonal
```

```
CC   antibodies.  The purified antigen migrated on SDS-PAGE as three
CC   close bands, with major component at 29 kD under non-reducing
CC   conditions.  It reacted with autoantibodies from patients sera
CC   indicating identity between Wegener's granulomatois autoantigen.
CC   On isofocusing gels it had a pI of 9.2-9.4.  It is a novel serine
CC   protease showing homology with leukocyte elastase and cathepsin G.
CC   The protein or monoclonal Abs can be used to test for the presence
CC   of autoantibodies diagnostic for Wegener's granulomatosis. In
CC   combination with myeloperoxidase (and/or Abs against it), p29 MAbs
CC   can also be used to test for autoantibodies associated with pauci
CC   immune necrotizing and/or crescentric glomerulonephritis.
SQ   Sequence   27 AA;

  Query Match           29.8%;  Score 45;  DB 3;  Length 27;
  Best Local Similarity  37.5%;  Pred. No. 1.22e+03;
  Matches    6;  Conservative    6;  Mismatches   4;  Indels   0;  Gaps   0;

Db     12 rpymaslqmrgnpgsh 27
          ||:::| :: :|:  ||
Qy      3 RPFKALVREKGHRPSH 18


RESULT   13
ID   W15386 standard; peptide; 15 AA.
AC   W15386;
DT   04-JUN-1997  (first entry)
DE   N-alpha-Ac-[Ala26,Phe27]-PYY(22-36).
KW   Analogue; peptide YY; PYY; regulation; neuropeptide Y;
KW   intestinal water; electrolyte secretion; cell proliferation;
KW   nutrient transport; lipolysis; blood flow.
OS   Synthetic.
FH   Key             Location/Qualifiers
FT   modified_site   1
FT                   /note= "N-alpha-acetyl-Ala"
FT   modified_site   15
FT                   /note= "amidated C-terminal"
PN   US5604203-A.
PD   18-FEB-1997.
PF   29-MAR-1993; 038534.
PR   29-MAR-1993; US-038534.
PR   19-AUG-1993; US-109326.
PR   24-OCT-1994; US-329151.
PA   (UYCI-) UNIV CINCINNATI.
PI   Balasubramaniam A;
DR   WPI; 97-144903/13.
PT   New peptide YY analogues - useful for decreasing excess intestinal
PT   water and electrolyte secretion, etc.
PS   Disclosure; Column 10; 24pp; English.
CC   The sequences given in W15357-90 represent analogues of peptide YY
CC   residues 22-36 or residues 25-36.  PYY shares a number of central
CC   and peripheral regulatory roles with neuropeptide Y, to which it is
CC   homologous.  These peptides are used for treatment of mammals to
CC   decrease excess intestinal water and electrolyte secretion, to regulate
CC   cell proliferation, to augment nutrient transport, to regulate lipolysis
CC   and to regulate blood flow.
SQ   Sequence   15 AA;

  Query Match           29.1%;  Score 44;  DB 21;  Length 15;
  Best Local Similarity  53.8%;  Pred. No. 1.50e+03;
  Matches    7;  Conservative    3;  Mismatches   2;  Indels   1;  Gaps   1;

Db      2 slraflnlvtrqr 14
          |||:|  || |::
Qy      1 SLRPFKALV-REK 12


RESULT   14
ID   W12816 standard; peptide; 15 AA.
AC   W12816;
DT   21-APR-1997  (first entry)
DE   Peptide chain ENCFE6VR5 of branched apogenic peptide.
KW   Branched apogenic peptide; apoptosis; inducer; erythrocyte; cancer cell;
KW   lymphocyte progenitor cell; mitogen-stimulated proliferating cell;
KW   nonquiescent cell.
OS   Synthetic.
PN   US5591717-A.
PD   07-JAN-1997.
PF   06-APR-1994; 224632.
PR   06-APR-1994; US-224632.
PA   (CHEN/) CHENEY C M.
PA   (HART/) HARTKE J R.
PA   (ROJK/) ROJKO J L.
PI   Cheney CM,  Hartke JR,  Rojko JL;
DR   WPI; 97-086658/08.
PT   New branched peptide(s) which induce apoptosis - and new peptides
PT   useful as chains in the branched peptides
PS   Claim 6; Column 24; 32pp; English.
CC   W12814-W12817 represent peptides used as chains for the branched apogenic
CC   peptide of the invention.  The branched apogenic peptides comprise a core
CC   sequence of at least 3, preferably at least 7 amino acids, which has at
CC   least 4 (preferably at least 8) peptide chains (such as this sequence)
CC   attached to it.  These sequences were synthesised as free unattached
CC   chains, and were later joined to the core sequence.  The core sequence is
CC   preferably a branched chain of lysine residues, synthesised as fully
CC   protected residues on a solid support.  The peptide chain sequences are
CC   then attached to the core, before the apogenic branched peptide is
CC   deprotected and released from the solid support by reacting it with
CC   anhydrous hydrogen fluoride.  The branched peptides can be used to induce
CC   apoptosis in cells in vitro, and in erythrocyte and lymphocyte progenitor
CC   cells in vivo.  The peptides can also be used to induce apoptosis in
CC   cancer cells, mitogen-stimulated proliferating cells and other
CC   nonquiescent cells, to study the process and effects of apoptosis.
SQ   Sequence   15 AA;

  Query Match           29.1%;  Score 44;  DB 20;  Length 15;
  Best Local Similarity  62.5%;  Pred. No. 1.50e+03;
  Matches    5;  Conservative    2;  Mismatches   1;  Indels   0;  Gaps   0;

Db      6 qkghrgth 13
          :|||| :|
Qy     11 EKGHRPSH 18


RESULT   15
ID   W51822 standard; peptide; 15 AA.
AC   W51822;
DT   13-OCT-1998  (first entry)
DE   Peptide YY analogue #33.
KW   peptide YY; cell proliferation; nutrient transport; lipolysis;
KW   electrolyte secretion; anti-secretory; intestinal water; antimotility.
OS   Synthetic.
OS   Mammalia.
FH   Key             Location/Qualifiers
FT   Modified_site   1
FT                   /note= "N-terminal acetyl"
FT   Modified_site   15
FT                   /note= "C-terminal amide"
PN   WO9820885-A1.
PD   22-MAY-1998.
PF   13-NOV-1996; U18374.
PR   13-NOV-1996; WO-U18374.
PA   (UYCI-) UNIV CINCINNATI.
PI   Balasubramaniam A;
DR   WPI; 98-322327/28.
PT   New analogue(s) of peptide YY - used, e.g. to control cell
PT   proliferation, nutrient transport, lipolysis and intestinal water
PT   and electrolyte secretion
PS   Disclosure; Page 18; 54pp; English.
CC   The invention relates to peptide YY analogues which may be used e.g. for
CC   decreasing excess intestinal water and electrolyte secretion in mammals,
CC   to regulate cell proliferation (especially intestinal cell
CC   proliferation), to increase nutrient transport, to regulate lipolysis
CC   and to regulate blood flow. The peptides exhibit antisecretory and
CC   antimotility properties and are especially useful in treatment of
CC   gastrointestinal disorders associated with excess intestinal electrolyte
CC   and water secretion as well as decreased absorption. The new peptides
```

CC are truncated versions of peptide YY. They interact solely with peptide
CC YY receptors and not with homologous receptors such as NPY Y1 and Y3,
CC thus minimising unwanted (ant)agonist side reactions. The present
CC sequence represents a peptide YY analogue.
SQ Sequence 15 AA;

Query Match 29.1%; Score 44; DB 33; Length 15;
Best Local Similarity 53.8%; Pred. No. 1.50e+03;
Matches 7; Conservative 3; Mismatches 2; Indels 1; Gaps 1;

```
Db      2 slraflnlvtrqr 14
          |||:|  || |::
Qy      1 SLRPFKALV-REK 12
```

Search completed: Wed Jun 23 14:56:08 1999
Job time : 133 secs.

****

MPSRCH (TM)

****

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Jun 22 15:00:44 1999; MasPar time 1.59 Seconds
128.003 Million cell updates/sec

Tabular output not generated.

Title: >US-08-644-289-1
Description: (1-20) from US08644289.pep
Perfect Score: 151
Sequence: 1 SLRPFKALVREKGHRPSHSC 20

Scoring table: PAM 150
Gap 15

Searched: 106580 seqs, 10152877 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 30

Database: a-issued
1:5A_COMB 2:5B_COMB 3:PCT9_COMB 4:backfiles1

Statistics: Mean 19.458; Variance 60.473; scale 0.322

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description	Pred. No.
1	136	90.1	21	1	US-08-644-	Sequence 1, Applicatio	2.71e-08
2	136	90.1	21	1	US-08-259-	Sequence 1, Applicatio	2.71e-08
3	85	56.3	20	1	US-08-644-	Sequence 4, Applicatio	3.32e-02
4	50	33.1	18	2	US-07-876-	Sequence 30, Applicati	1.85e+02
5	48	31.8	17	1	US-08-644-	Sequence 1, Applicatio	2.89e+02
6	46	30.5	16	1	US-08-313-	Sequence 11, Applicati	4.48e+02
7	46	30.5	29	1	US-08-313-	Sequence 7, Applicatio	4.48e+02
8	45	29.8	12	2	US-08-188-	Sequence 32, Applicati	5.56e+02
9	45	29.8	14	1	US-08-232-	Sequence 41, Applicati	5.56e+02
10	45	29.8	27	1	US-07-603-	Sequence 1, Applicatio	5.56e+02
11	44	29.1	15	1	US-08-224-	Sequence 5, Applicatio	6.88e+02
12	44	29.1	15	1	US-08-224-	Sequence 4, Applicatio	6.88e+02
13	44	29.1	20	1	US-07-882-	Sequence 7, Applicatio	6.88e+02
14	43	28.5	15	1	US-08-329-	Sequence 28, Applicati	8.50e+02
15	43	28.5	21	1	US-08-786-	Sequence 66, Applicati	8.50e+02
16	43	28.5	21	1	US-08-786-	Sequence 63, Applicati	8.50e+02
17	43	28.5	21	1	US-08-786-	Sequence 67, Applicati	8.50e+02
18	43	28.5	21	1	US-08-786-	Sequence 64, Applicati	8.50e+02
19	43	28.5	21	1	US-08-786-	Sequence 65, Applicati	8.50e+02
20	43	28.5	22	3	PCT-US95-1	Sequence 3, Applicatio	8.50e+02
21	43	28.5	22	1	US-08-485-	Sequence 3, Applicatio	8.50e+02
22	43	28.5	23	3	PCT-US95-0	Sequence 57, Applicati	8.50e+02
23	43	28.5	23	3	PCT-US95-0	Sequence 57, Applicati	8.50e+02
24	43	28.5	24	1	US-08-786-	Sequence 60, Applicati	8.50e+02
25	43	28.5	24	1	US-08-786-	Sequence 58, Applicati	8.50e+02
26	43	28.5	24	1	US-08-786-	Sequence 56, Applicati	8.50e+02
27	43	28.5	24	1	US-08-786-	Sequence 59, Applicati	8.50e+02
28	43	28.5	27	3	PCT-US95-0	Sequence 59, Applicati	8.50e+02
29	43	28.5	27	3	PCT-US95-0	Sequence 58, Applicati	8.50e+02
30	43	28.5	27	3	PCT-US95-0	Sequence 58, Applicati	8.50e+02
31	43	28.5	27	3	PCT-US95-0	Sequence 59, Applicati	8.50e+02
32	43	28.5	28	1	US-08-786-	Sequence 42, Applicati	8.50e+02
33	43	28.5	28	1	US-08-786-	Sequence 43, Applicati	8.50e+02
34	43	28.5	28	1	US-08-786-	Sequence 45, Applicati	8.50e+02
35	43	28.5	28	1	US-08-786-	Sequence A4, Applicati	8.50e+02
36	43	28.5	28	1	US-08-786-	Sequence 46, Applicati	8.50e+02
37	42	27.8	15	1	US-08-329-	Sequence 16, Applicati	1.05e+03
38	42	27.8	15	1	US-08-329-	Sequence 7, Applicatio	1.05e+03
39	42	27.8	15	1	US-08-329-	Sequence 30, Applicati	1.05e+03
40	42	27.8	15	1	US-08-329-	Sequence 17, Applicati	1.05e+03
41	42	27.8	15	1	US-08-329-	Sequence 13, Applicati	1.05e+03
42	42	27.8	15	1	US-08-329-	Sequence 27, Applicati	1.05e+03
43	42	27.8	15	1	US-08-329-	Sequence 4, Applicatio	1.05e+03
44	42	27.8	15	1	US-08-329-	Sequence 3, Applicatio	1.05e+03
45	42	27.8	16	1	US-08-488-	Sequence 33, Applicati	1.05e+03
46	42	27.8	18	3	PCT-US93-0	Sequence 2, Applicatio	1.05e+03
47	42	27.8	18	1	US-08-383-	Sequence 2, Applicatio	1.05e+03
48	42	27.8	24	3	PCT-US93-0	Sequence 145, Applicat	1.05e+03
49	42	27.8	24	2	US-08-480-	Sequence 145, Applicat	1.05e+03
50	42	27.8	24	2	US-08-488-	Sequence 145, Applicat	1.05e+03
51	42	27.8	26	2	US-08-488-	Sequence 144, Applicat	1.05e+03
52	42	27.8	26	2	US-08-480-	Sequence 144, Applicat	1.05e+03
53	42	27.8	26	3	PCT-US93-0	Sequence 144, Applicat	1.05e+03
54	41	27.2	17	3	PCT-US95-1	Sequence 42, Applicati	1.29e+03
55	41	27.2	17	2	US-08-323-	Sequence 42, Applicati	1.29e+03
56	41	27.2	17	2	US-08-413-	Sequence 42, Applicati	1.29e+03
57	41	27.2	21	2	US-08-707-	Sequence 69, Applicati	1.29e+03
58	41	27.2	21	2	US-08-477-	Sequence 97, Applicati	1.29e+03
59	41	27.2	21	2	US-08-642-	Sequence 82, Applicati	1.29e+03

Note: Post-processor removed 941 summaries from list due to search parameters chosen.

ALIGNMENTS

```
RESULT    1
ID   US-08-644-291-1     STANDARD;     PRT;   21 AA.
XX
AC   XXXXXX
XX
DT
XX
DE   Sequence 1, Application US/08644291
XX
CC    Sequence 1, Application US/08644291
CC    Patent No. 5726024
CC     GENERAL INFORMATION:
CC       APPLICANT:  Kulesz-Martin, Molly F.
CC       TITLE OF INVENTION:  p53as PROTEIN AND ANTIBODY
CC       TITLE OF INVENTION:  THEREFOR
CC       NUMBER OF SEQUENCES:  9
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Dunn & Associates
CC         STREET:  P.O. Box 96
CC         CITY:  Newfane
CC         STATE:  New York
CC         COUNTRY:  U.S.A.
CC         ZIP:  14108
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Diskette - 3.50 inch, 1.44 Mb
CC         MEDIUM TYPE:  Storage
CC         COMPUTER:  Victor 300 SX/25 (IBM PC Compatible)
CC         OPERATING SYSTEM:  MS-DOS Version 5.0
CC         SOFTWARE:  Wordstar Professional Release 4
CC       CURRENT APPLICATION DATA:
```

```
CC         APPLICATION NUMBER:  US/08/644,291
CC         FILING DATE:  10-May-1996
CC         CLASSIFICATION:  530
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  08/259,612
CC         FILING DATE:  14-Jun-1994
CC         CLASSIFICATION:  530
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  08/195,952
CC         FILING DATE:  11-Feb-1994
CC         CLASSIFICATION:  530
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  08/100,496
CC         FILING DATE:  02-Aug-1993
CC         CLASSIFICATION:  530
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Dunn, Michael L.
CC         REGISTRATION NUMBER:  25,330
CC         REFERENCE/DOCKET NUMBER:  RPP:135E US
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  (716) 433-1661
CC         TELEFAX:  (716) 433-1665
CC     INFORMATION FOR SEQ ID NO:  1:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  21
CC         TYPE:  Amino Acid
CC         STRANDEDNESS:  Unknown
CC         TOPOLOGY:  Unknown
CC       MOLECULE TYPE:  Peptide
CC       HYPOTHETICAL:  No
CC       ANTI-SENSE:  No
CC       FRAGMENT TYPE:
CC       ORIGINAL SOURCE:
CC         ORGANISM:
CC         STRAIN:
CC         INDIVIDUAL ISOLATE:
CC         DEVELOPMENTAL STAGE:
CC         HAPLOTYPE:
CC         TISSUE TYPE:
CC         CELL TYPE:
CC         CELL LINE:
CC         ORGANELLE:
CC       IMMEDIATE SOURCE:
CC         LIBRARY:
CC         CLONE:
CC       POSITION IN GENOME:
CC         CHROMOSOME/SEGMENT:  17
CC         MAP POSITION:  intron 10
CC         UNITS:
CC       FEATURE:
CC         NAME/KEY:
CC         LOCATION:
CC         IDENTIFICATION METHOD:
CC         OTHER INFORMATION:
CC       PUBLICATION INFORMATION:
CC         AUTHORS:
CC         TITLE:
CC         JOURNAL:
CC         VOLUME:
CC         ISSUE:
CC         PAGES:
CC         DATE:
CC         DOCUMENT NUMBER:
CC         FILING DATE:
CC         PUBLICATION DATE:
CC         RELEVANT RESIDUES IN SEQ ID NO:
SQ   SEQUENCE   21 AA; 2393 MW; 2418 CN;

  Query Match           90.1%;  Score 136;  DB 1;  Length 21;
  Best Local Similarity  95.2%;  Pred. No. 2.71e-08;
  Matches   20;  Conservative    0;  Mismatches   0;  Indels   1;  Gaps   1;

Db      1 SLRPFKALVREKGHRPSSHSC 21
```

```
                ||||||||||||||||| |||
Qy      1 SLRPFKALVREKGHRPS-HSC 20


RESULT    2
ID   US-08-259-612A-1     STANDARD;     PRT;   21 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 1, Application US/08259612A
XX
CC    Sequence 1, Application US/08259612A
CC    Patent No. 5688918
CC     GENERAL INFORMATION:
CC       APPLICANT:  Kulesz-Martin, Molly F.
CC       TITLE OF INVENTION:  p53as PROTEIN AND ANTIBODY
CC       TITLE OF INVENTION:  THEREFOR
CC       NUMBER OF SEQUENCES:  9
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Dunn & Associates, P.C.
CC         STREET:  P.O. Box 96
CC         CITY:  Newfane
CC         STATE:  New York
CC         COUNTRY:  U.S.A.
CC         ZIP:  14108
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Diskette - 3.50 inch, 1.44 Mb
CC         MEDIUM TYPE:  Storage
CC         COMPUTER:  Victor 300 SX/25 (IBM PC Compatible)
CC         OPERATING SYSTEM:  MS-DOS Version 5.0
CC         SOFTWARE:  Wordstar Professional Release 4
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/259,612A
CC         FILING DATE:  14-Jun-1994
CC         CLASSIFICATION:  530
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  08/195,952
CC         FILING DATE:  14-Feb-1994
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Dunn, Michael L.
CC         REGISTRATION NUMBER:  25,330
CC         REFERENCE/DOCKET NUMBER:  RPP:135B US
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  (716) 433-1661
CC         TELEFAX:  (716) 433-1665
CC     INFORMATION FOR SEQ ID NO:  1:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  21
CC         TYPE:  Amino Acid
CC         STRANDEDNESS:  Unknown
CC         TOPOLOGY:  Unknown
CC       MOLECULE TYPE:  Peptide
CC       HYPOTHETICAL:  No
CC       ANTI-SENSE:  No
CC       FRAGMENT TYPE:
CC       ORIGINAL SOURCE:
CC         ORGANISM:
CC         STRAIN:
CC         INDIVIDUAL ISOLATE:
CC         DEVELOPMENTAL STAGE:
CC         HAPLOTYPE:
CC         TISSUE TYPE:
CC         CELL TYPE:
CC         CELL LINE:
CC         ORGANELLE:
CC       IMMEDIATE SOURCE:
CC         LIBRARY:
CC         CLONE:
CC       POSITION IN GENOME:
CC         CHROMOSOME/SEGMENT:  17
CC         MAP POSITION:  intron 10
```

```
CC         UNITS:
CC       FEATURE:
CC         NAME/KEY:
CC         LOCATION:
CC         IDENTIFICATION METHOD:
CC         OTHER INFORMATION:
CC       PUBLICATION INFORMATION:
CC         AUTHORS:
CC         TITLE:
CC         JOURNAL:
CC         VOLUME:
CC         ISSUE:
CC         PAGES:
CC         DATE:
CC         DOCUMENT NUMBER:
CC         FILING DATE:
CC         PUBLICATION DATE:
CC         RELEVANT RESIDUES IN SEQ ID NO:
SQ   SEQUENCE   21 AA; 2393 MW; 2418 CN;

  Query Match           90.1%;  Score 136;  DB 1;  Length 21;
  Best Local Similarity  95.2%;  Pred. No. 2.71e-08;
  Matches    20;  Conservative    0;  Mismatches   0;  Indels   1;  Gaps   1;

Db      1 SLRPFKALVREKGHRPSSHSC 21
          |||||||||||||||| |||
Qy      1 SLRPFKALVREKGHRPS-HSC 20


RESULT    3
ID   US-08-644-456-4     STANDARD;     PRT;   20 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 4, Application US/08644456
XX
CC    Sequence 4, Application US/08644456
CC    Patent No. 5747650
CC     GENERAL INFORMATION:
CC       APPLICANT:  Kulesz-Martin, Molly F.
CC       TITLE OF INVENTION:  p53as PROTEIN AND ANTIBODY THEREFOR
CC       NUMBER OF SEQUENCES:  5
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Dunn & Associates
CC         STREET:  P.O. Box 96
CC         CITY:  Newfane
CC         STATE:  New York
CC         COUNTRY:  U.S.A.
CC         ZIP:  14108
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Diskette - 3.50 inch, 1.44 Mb storage
CC         COMPUTER:  Victor 300 SX/25 (IBM PC Compatible)
CC         OPERATING SYSTEM:  MS-DOS Version 5.0
CC         SOFTWARE:  Wordstar Professional Release 4
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/644,456
CC         FILING DATE:  10-May-1996
CC         CLASSIFICATION:  530
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  08/100,496
CC         FILING DATE:  2-Aug-1993
CC         CLASSIFICATION:  530
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Dunn, Michael L.
CC         REGISTRATION NUMBER:  25,330
CC         REFERENCE/DOCKET NUMBER:  RPP:135C US
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:   (716) 433-1661
CC         TELEFAX:  (716) 433-1665
CC     INFORMATION FOR SEQ ID NO:  4:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  20
CC         TYPE:  Amino Acids
CC         STRANDEDNESS:  unknown
CC         TOPOLOGY:  unknown
CC       MOLECULE TYPE:  Peptide
CC       HYPOTHETICAL:  deduced from intron 10 sequences p53 gene
CC       ANTI-SENSE:
CC       FRAGMENT TYPE:
CC       ORIGINAL SOURCE:
CC         ORGANISM:  Human
CC         STRAIN:
CC         INDIVIDUAL ISOLATE:
CC         DEVELOPMENTAL STAGE:
CC         HAPLOTYPE:
CC         TISSUE TYPE:
CC         CELL TYPE:
CC         CELL LINE:
CC         ORGANELLE:
CC       IMMEDIATE SOURCE:
CC         LIBRARY:  deduced translation from nucleotides in
CC         LIBRARY:  Genbank nucleic acid database accession #54156,
CC         LIBRARY:  Locus HSP53G
CC         CLONE:
CC       POSITION IN GENOME:
CC         CHROMOSOME/SEGMENT:  17
CC         MAP POSITION:  p53 gene, at 18530 to 18589
CC         UNITS:
CC       FEATURE:  n/a
CC         NAME/KEY:
CC         LOCATION:
CC         IDENTIFICATION METHOD:
CC         OTHER INFORMATION:
CC       PUBLICATION INFORMATION:
CC         AUTHORS:
CC         TITLE:
CC         JOURNAL:
CC         VOLUME:
CC         ISSUE:
CC         PAGES:
CC         DATE:
CC         DOCUMENT NUMBER:
CC         FILING DATE:
CC         PUBLICATION DATE:
CC         RELEVANT RESIDUES IN SEQ ID NO:
SQ   SEQUENCE   20 AA; 2256 MW; 2309 CN;

  Query Match           56.3%;  Score 85;  DB 1;  Length 20;
  Best Local Similarity 100.0%;  Pred. No. 3.32e-02;
  Matches    11;  Conservative    0;  Mismatches   0;  Indels   0;  Gaps   0;

Db      1 REKGHRPSHSC 11
          ||||||||||||
Qy     10 REKGHRPSHSC 20


RESULT    4
ID   US-07-876-941A-30     STANDARD;     PRT;   18 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 30, Application US/07876941A
XX
CC    Sequence 30, Application US/07876941A
CC    Patent No. 5885768
CC     GENERAL INFORMATION:
CC       APPLICANT:  Reyes, Gregory R.
CC       APPLICANT:  Bradley, Daniel W.
CC       APPLICANT:  Tam, Albert W.
CC       APPLICANT:  Mitchell, Carl
CC       TITLE OF INVENTION:  Hepatitis E Virus Peptide Antigen and
CC       TITLE OF INVENTION:  Antibodies
```

```
CC       NUMBER OF SEQUENCES:  76
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Dehlinger & Associates
CC         STREET:  350 Cambridge Avenue, Suite 250
CC         CITY:  Palo Alto
CC         STATE:  CA
CC         COUNTRY:  USA
CC         ZIP:  94306
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Floppy disk
CC         COMPUTER:  IBM PC compatible
CC         OPERATING SYSTEM:  PC-DOS/MS-DOS
CC         SOFTWARE:  PatentIn Release #1.0, Version #1.25
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/07/876,941A
CC         FILING DATE:  01-MAY-1992
CC         CLASSIFICATION:  435
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 822,335
CC         FILING DATE:  17-JAN-1992
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 505,888
CC         FILING DATE:  05-APRIL-1990
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 420,921
CC         FILING DATE:  13-OCTOBER-1989
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 367,486
CC         FILING DATE:  16-JUNE-1989
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 336,672
CC         FILING DATE:  11-APRIL-1989
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 208,997
CC         FILING DATE:  17-JUNE-1988
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Sholtz, Charles K.
CC         REGISTRATION NUMBER:  38,615
CC         REFERENCE/DOCKET NUMBER:  4600-0093.33
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  (415) 324-0880
CC         TELEFAX:  (415) 324-0960
CC     INFORMATION FOR SEQ ID NO:  30:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  18 amino acids
CC         TYPE:  amino acid
CC         STRANDEDNESS:  single
CC         TOPOLOGY:  unknown
CC       MOLECULE TYPE:  peptide
CC       HYPOTHETICAL:  NO
CC       ANTI-SENSE:  NO
CC       ORIGINAL SOURCE:
CC         INDIVIDUAL ISOLATE:  Fig. 11, ORF 1, aa 1237-1254
SQ   SEQUENCE   18 AA; 2035 MW; 1618 CN;

  Query Match           33.1%;  Score 50;  DB 2;  Length 18;
  Best Local Similarity  46.7%;  Pred. No. 1.85e+02;
  Matches    7;  Conservative    2;  Mismatches   6;  Indels   0;  Gaps   0;

Db      3 ISAFHQLAEELGHRP 17
          : :|  |  | ||||
Qy      2 LRPFKALVREKGHRP 16


RESULT    5
ID   US-08-644-456-1     STANDARD;     PRT;   17 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 1, Application US/08644456
XX
CC   Sequence 1, Application US/08644456
CC   Patent No. 5747650
CC    GENERAL INFORMATION:
CC      APPLICANT:  Kulesz-Martin, Molly F.
CC      TITLE OF INVENTION:  p53as PROTEIN AND ANTIBODY THEREFOR
CC      NUMBER OF SEQUENCES:  5
CC      CORRESPONDENCE ADDRESS:
CC        ADDRESSEE:  Dunn & Associates
CC        STREET:  P.O. Box 96
CC        CITY:  Newfane
CC        STATE:  New York
CC        COUNTRY:  U.S.A.
CC        ZIP:  14108
CC      COMPUTER READABLE FORM:
CC        MEDIUM TYPE:  Diskette - 3.50 inch, 1.44 Mb storage
CC        COMPUTER:  Victor 300 SX/25 (IBM PC Compatible)
CC        OPERATING SYSTEM:  MS-DOS Version 5.0
CC        SOFTWARE:  Wordstar Professional Release 4
CC      CURRENT APPLICATION DATA:
CC        APPLICATION NUMBER:  US/08/644,456
CC        FILING DATE:  10-May-1996
CC        CLASSIFICATION:  530
CC      PRIOR APPLICATION DATA:
CC        APPLICATION NUMBER:  08/100,496
CC        FILING DATE:  2-Aug-1993
CC        CLASSIFICATION:  530
CC      ATTORNEY/AGENT INFORMATION:
CC        NAME:  Dunn, Michael L.
CC        REGISTRATION NUMBER:  25,330
CC        REFERENCE/DOCKET NUMBER:  RPP:135C US
CC      TELECOMMUNICATION INFORMATION:
CC        TELEPHONE:  (716) 433-1661
CC        TELEFAX:  (716) 433-1665
CC     INFORMATION FOR SEQ ID NO:  1:
CC      SEQUENCE CHARACTERISTICS:
CC        LENGTH:  17
CC        TYPE:  amino acids
CC        STRANDEDNESS:  n/a
CC        TOPOLOGY:  n/a
CC      MOLECULE TYPE:  peptide
CC      HYPOTHETICAL:  no
CC      ANTI-SENSE:  no
CC      FRAGMENT TYPE:  n/a
CC      ORIGINAL SOURCE:
CC        ORGANISM:  mouse
CC        STRAIN:  n/a
CC        INDIVIDUAL ISOLATE:  n/a
CC        DEVELOPMENTAL STAGE:  n/a
CC        HAPLOTYPE:  n/a
CC        TISSUE TYPE:  n/a
CC        CELL TYPE:  n/a
CC        CELL LINE:  n/a
CC        ORGANELLE:  n/a
CC      IMMEDIATE SOURCE:  sequenced from cDNA clone from mouse
CC      IMMEDIATE SOURCE:  epidermal cell RNA, Genbank Accession #M13874
CC        LIBRARY:  plasmid p6.3
CC        CLONE:
CC      POSITION IN GENOME:
CC        CHROMOSOME/SEGMENT:  11
CC        MAP POSITION:  p53 gene
CC        UNITS:
CC      FEATURE:  n/a
CC        NAME/KEY:
CC        LOCATION:
CC        IDENTIFICATION METHOD:
CC        OTHER INFORMATION:
CC      PUBLICATION INFORMATION:
CC        AUTHORS:  Kulesz-Martin et al.
CC        TITLE:  Endogenous p53 Protein Generated From Wild
CC        TITLE:  Type Alternatively Spliced  P53 RNA in Mouse
CC        JOURNAL:  Mol. Cell. Biol.
CC        VOLUME:  14
CC        ISSUE:  3
```

```
CC         PAGES:  1698-1708
CC         DATE:  March, 1994
CC         AUTHORS:  Han, K.A. and Kulesz-Martin, M.F.
CC         TITLE:  Alternatively Spliced p53 RNA in Transformed
CC         TITLE:  and No. 5747650mal Cells of Different Tissue Types
CC         JOURNAL:  Nucleic Acids Res.
CC         VOLUME:  20
CC         ISSUE:  8
CC         PAGES:  1979-1981
CC         DATE:  1992
CC         AUTHORS:  Arai, N. et al.
CC         TITLE:  Immunologically Distinct p53 Molecules Generated
CC         TITLE:  by Alternative Splicing
CC         JOURNAL:  Mol. and Cell. Biol.
CC         VOLUME:  6
CC         ISSUE:
CC         PAGES:  3232-3239
CC         DATE:  1986
CC         DOCUMENT NUMBER:
CC         FILING DATE:
CC         PUBLICATION DATE:
CC         RELEVANT RESIDUES IN SEQ ID NO:
SQ   SEQUENCE   17 AA; 1944 MW; 1303 CN;

  Query Match           31.8%;  Score 48;  DB 1;  Length 17;
  Best Local Similarity  55.6%;  Pred. No. 2.89e+02;
  Matches     5;  Conservative    3;  Mismatches   1;  Indels   0;  Gaps   0;

Db      4 RAFQALIKE 12
          |:| ||::|
Qy      3 RPFKALVRE 11


RESULT    6
ID   US-08-313-681A-11     STANDARD;     PRT;   16 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 11, Application US/08313681A
XX
CC    Sequence 11, Application US/08313681A
CC    Patent No. 5618675
CC     GENERAL INFORMATION:
CC       APPLICANT:  Larrick, James W.
CC       APPLICANT:  Wright, Susan C.
CC       APPLICANT:  Hirata, Mishimasa
CC       TITLE OF INVENTION:  Human Cationic Proteins Having
CC       TITLE OF INVENTION:  Lipopolysaccharide Binding and Anti-Coagulant Activity
CC       NUMBER OF SEQUENCES:  30
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Townsend and Townsend Khourie and Crew
CC         STREET:  One Market Plaza, Steuart Tower, Suite 2000
CC         CITY:  San Francisco
CC         STATE:  California
CC         COUNTRY:  USA
CC         ZIP:  94105
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Floppy disk
CC         COMPUTER:  IBM PC compatible
CC         OPERATING SYSTEM:  PC-DOS/MS-DOS
CC         SOFTWARE:  PatentIn Release #1.0, Version #1.25
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/313,681A
CC         FILING DATE:
CC         CLASSIFICATION:  435
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Heslin, James M.
CC         REGISTRATION NUMBER:  29,541
CC         REFERENCE/DOCKET NUMBER:  15325-9-1
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  415-326-2400
CC         TELEFAX:  415-326-2422
CC      INFORMATION FOR SEQ ID NO:  11:
CC        SEQUENCE CHARACTERISTICS:
CC          LENGTH:  16 amino acids
CC          TYPE:  amino acid
CC          STRANDEDNESS:  single
CC          TOPOLOGY:  linear
CC        MOLECULE TYPE:  peptide
SQ   SEQUENCE   16 AA; 2071 MW; 1188 CN;

  Query Match           30.5%;  Score 46;  DB 1;  Length 16;
  Best Local Similarity  45.5%;  Pred. No. 4.48e+02;
  Matches     5;  Conservative    3;  Mismatches   3;  Indels   0;  Gaps   0;

Db      6 LRKFRNKIKEK 16
          || |:  ::||
Qy      2 LRPFKALVREK 12


RESULT    7
ID   US-08-313-681A-7     STANDARD;     PRT;   29 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 7, Application US/08313681A
XX
CC    Sequence 7, Application US/08313681A
CC    Patent No. 5618675
CC     GENERAL INFORMATION:
CC       APPLICANT:  Larrick, James W.
CC       APPLICANT:  Wright, Susan C.
CC       APPLICANT:  Hirata, Mishimasa
CC       TITLE OF INVENTION:  Human Cationic Proteins Having
CC       TITLE OF INVENTION:  Lipopolysaccharide Binding and Anti-Coagulant Activity
CC       NUMBER OF SEQUENCES:  30
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Townsend and Townsend Khourie and Crew
CC         STREET:  One Market Plaza, Steuart Tower, Suite 2000
CC         CITY:  San Francisco
CC         STATE:  California
CC         COUNTRY:  USA
CC         ZIP:  94105
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Floppy disk
CC         COMPUTER:  IBM PC compatible
CC         OPERATING SYSTEM:  PC-DOS/MS-DOS
CC         SOFTWARE:  PatentIn Release #1.0, Version #1.25
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/313,681A
CC         FILING DATE:
CC         CLASSIFICATION:  435
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Heslin, James M.
CC         REGISTRATION NUMBER:  29,541
CC         REFERENCE/DOCKET NUMBER:  15325-9-1
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  415-326-2400
CC         TELEFAX:  415-326-2422
CC      INFORMATION FOR SEQ ID NO:  7:
CC        SEQUENCE CHARACTERISTICS:
CC          LENGTH:  29 amino acids
CC          TYPE:  amino acid
CC          STRANDEDNESS:  single
CC          TOPOLOGY:  linear
CC        MOLECULE TYPE:  peptide
CC        FEATURE:
CC          NAME/KEY:  Region
CC          LOCATION:  23
CC          OTHER INFORMATION:  /note= "Xaa is Asp or Lys"
CC        FEATURE:
CC          NAME/KEY:  Region
```

```
CC         LOCATION:  26
CC         OTHER INFORMATION:  /note= "Xaa is a Gln or Ile"
CC       FEATURE:
CC         NAME/KEY:  Region
CC         LOCATION:  27
CC         OTHER INFORMATION:  /note= "Xaa is a Gly or Gln"
SQ   SEQUENCE   29 AA; 3536 MW; 5084 CN;

  Query Match           30.5%;  Score 46;  DB 1;  Length 29;
  Best Local Similarity  45.5%;  Pred. No. 4.48e+02;
  Matches    5;  Conservative    3;  Mismatches   3;  Indels   0;  Gaps   0;

Db      6 LRKFRNKIKEK 16
          || |:  ::||
Qy      2 LRPFKALVREK 12


RESULT    8
ID   US-08-188-583-32     STANDARD;     PRT;   12 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 32, Application US/08188583
XX
CC    Sequence 32, Application US/08188583
CC    Patent No. 5851813
CC     GENERAL INFORMATION:
CC       APPLICANT:  Desrosiers, Ronald C.
CC       TITLE OF INVENTION:  PRIMATE LENTIVIRUS VACCINES
CC       NUMBER OF SEQUENCES:  57
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Fish & Richardson
CC         STREET:  225 Franklin Street
CC         CITY:  Boston
CC         STATE:  Massachusetts
CC         COUNTRY:  U.S.A.
CC         ZIP:  02110-2804
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
CC         COMPUTER:  IBM PS/2 Model 50Z or 55SX
CC         OPERATING SYSTEM:  IBM P.C. DOS (Version 3.30)
CC         SOFTWARE:  WordPerfect (Version 5.0)
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/188,583
CC         FILING DATE:
CC         CLASSIFICATION:  435
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  07/727,494
CC         FILING DATE:  July 9, 1991
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  07/551,945
CC         FILING DATE:  July 12, 1990
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Freeman, John W.
CC         REGISTRATION NUMBER:  Reg. No. 5851813 29,066
CC         REFERENCE/DOCKET NUMBER:  00246/079002
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  (617) 542-5070
CC         TELEFAX:  (617) 542-8906
CC         TELEX:  200154
CC     INFORMATION FOR SEQ ID NO:  32:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  12
CC         TYPE:  amino acid
CC         STRANDEDNESS:
CC         TOPOLOGY:  linear
SQ   SEQUENCE   12 AA; 1318 MW; 741 CN;

  Query Match           29.8%;  Score 45;  DB 2;  Length 12;
  Best Local Similarity  75.0%;  Pred. No. 5.56e+02;
  Matches    6;  Conservative    1;  Mismatches   1;  Indels   0;  Gaps   0;

Db      1 KGHRGSHT 8
          |||| ||:
Qy     12 KGHRPSHS 19


RESULT    9
ID   US-08-232-453A-41     STANDARD;     PRT;   14 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 41, Application US/08232453A
XX
CC    Sequence 41, Application US/08232453A
CC    Patent No. 5589568
CC     GENERAL INFORMATION:
CC       APPLICANT:  HIGASHIJIMA, TSUTOMU
CC       APPLICANT:  ROSS, ELLIOTT M.
CC       TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
CC       TITLE OF INVENTION:  MODULATING G PROTEIN ACTION
CC       NUMBER OF SEQUENCES:  71
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  ARNOLD, WHITE & DURKEE
CC         STREET:  P.O.BOX 4433
CC         CITY:  HOUSTON
CC         STATE:  TX
CC         COUNTRY:  USA
CC         ZIP:  77210
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  FLOPPY DISK
CC         COMPUTER:  IBM PC COMPATIBLE
CC         OPERATING SYSTEM:  PC-DOS/MS-DOS
CC         SOFTWARE:  WORDPERFECT 5.1
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/232,453A
CC         FILING DATE:  APRIL 22, 1994
CC         CLASSIFICATION:  514
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 07/748,319
CC         FILING DATE:  AUGUST 21, 1991
CC         CLASSIFICATION:  514
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  PARKER, DAVID L.
CC         REGISTRATION NUMBER:  32,165
CC         REFERENCE/DOCKET NUMBER:  UTSD:253/PAR
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  (512) 418-3000
CC         TELEFAX:  (512) 474-7577
CC     INFORMATION FOR SEQ ID NO:  41:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  14 amino acids
CC         TYPE:  amino acid
CC         STRANDEDNESS:  single
CC         TOPOLOGY:  linear
SQ   SEQUENCE   14 AA; 1564 MW; 590 CN;

  Query Match           29.8%;  Score 45;  DB 1;  Length 14;
  Best Local Similarity  50.0%;  Pred. No. 5.56e+02;
  Matches    5;  Conservative    4;  Mismatches   1;  Indels   0;  Gaps   0;

Db      2 NLRALRALAR 11
          :||:::|| |
Qy      1 SLRPFKALVR 10


RESULT   10
ID   US-07-603-782A-1     STANDARD;     PRT;   27 AA.
XX
AC   xxxxxx
XX
DT
```

```
XX
DE   Sequence 1, Application US/07603782A
XX
CC    Sequence 1, Application US/07603782A
CC    Patent No. 5200319
CC     GENERAL INFORMATION:
CC       APPLICANT:  Arnaout, Amin M.
CC       APPLICANT:  McCluskey, Robert T.
CC       APPLICANT:  Niles, John L.
CC       TITLE OF INVENTION:  Diagnosis of Glomerulonephritis
CC       NUMBER OF SEQUENCES:  1
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Fish & Richardson
CC         STREET:  225 Franklin Street
CC         CITY:  Boston
CC         STATE:  Massachusetts
CC         COUNTRY:  U.S.A.
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
CC         COMPUTER:  IBM PS/2 Model 50Z or 55SX
CC         OPERATING SYSTEM:  IBM P.C. DOS (Version 3.30)
CC         SOFTWARE:  WordPerfect (Version 5.0)
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/07/603,782A
CC         FILING DATE:  19901025
CC         CLASSIFICATION:  436
CC       PRIOR APPLICATION DATA:
CC       PRIOR APPLICATION DATA:  including application
CC       PRIOR APPLICATION DATA:  described below:    1
CC         APPLICATION NUMBER:  07/428,286
CC         FILING DATE:  27-OCT-1989
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Clark, Paul T.
CC         REGISTRATION NUMBER:  30,162
CC         REFERENCE/DOCKET NUMBER:  00786/034002
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  (617) 542-5070
CC         TELEFAX:  (617) 542-8906
CC         TELEX:  200154
CC     INFORMATION FOR SEQ ID NO:  1:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  27
CC         TYPE:  AMINO ACID
CC         TOPOLOGY:  linear
SQ   SEQUENCE   27 AA; 2915 MW; 3695 CN;

  Query Match           29.8%;  Score 45;  DB 1;  Length 27;
  Best Local Similarity  37.5%;  Pred. No. 5.56e+02;
  Matches     6;  Conservative     6;  Mismatches   4;  Indels   0;  Gaps   0;

Db     12 RPYMASLQMRGNPGSH 27
           ||::| :: :|:  ||
Qy      3 RPFKALVREKGHRPSH 18


RESULT   11
ID   US-08-224-632A-5     STANDARD;     PRT;   15 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 5, Application US/08224632A
XX
CC    Sequence 5, Application US/08224632A
CC    Patent No. 5591717
CC     GENERAL INFORMATION:
CC       APPLICANT:  Rojko, Jennifer L.
CC       APPLICANT:  Hartke, James R.
CC       APPLICANT:  Cheney, Carolyn M.
CC       TITLE OF INVENTION:  Branched Apogenic Peptide for Inducing
CC       TITLE OF INVENTION:  Apoptosis
CC       NUMBER OF SEQUENCES:  6
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Calfee Halter & Griswold
CC         STREET:  800 Superior Avenue, Suite 1800
CC         CITY:  Cleveland
CC         STATE:  Ohio
CC         COUNTRY:  USA
CC         ZIP:  44114
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Floppy disk
CC         COMPUTER:  IBM PC compatible
CC         OPERATING SYSTEM:  PC-DOS/MS-DOS
CC         SOFTWARE:  PatentIn Release #1.0, Version #1.30
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/224,632A
CC         FILING DATE:
CC         CLASSIFICATION:  530
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Golrick, Mary E.
CC         REGISTRATION NUMBER:  34,829
CC         REFERENCE/DOCKET NUMBER:  22727-00111
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  216 622 8458
CC         TELEFAX:  216 241 0816
CC     INFORMATION FOR SEQ ID NO:  5:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  15 amino acids
CC         TYPE:  amino acid
CC         STRANDEDNESS:
CC         TOPOLOGY:  linear
CC       MOLECULE TYPE:  peptide
CC       HYPOTHETICAL:  NO
SQ   SEQUENCE   15 AA; 1770 MW; 1315 CN;

  Query Match           29.1%;  Score 44;  DB 1;  Length 15;
  Best Local Similarity  62.5%;  Pred. No. 6.88e+02;
  Matches     5;  Conservative     2;  Mismatches   1;  Indels   0;  Gaps   0;

Db      6 QKGHRGTH 13
          :|||| :|
Qy     11 EKGHRPSH 18


RESULT   12
ID   US-08-224-632A-4     STANDARD;     PRT;   15 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 4, Application US/08224632A
XX
CC    Sequence 4, Application US/08224632A
CC    Patent No. 5591717
CC     GENERAL INFORMATION:
CC       APPLICANT:  Rojko, Jennifer L.
CC       APPLICANT:  Hartke, James R.
CC       APPLICANT:  Cheney, Carolyn M.
CC       TITLE OF INVENTION:  Branched Apogenic Peptide for Inducing
CC       TITLE OF INVENTION:  Apoptosis
CC       NUMBER OF SEQUENCES:  6
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Calfee Halter & Griswold
CC         STREET:  800 Superior Avenue, Suite 1800
CC         CITY:  Cleveland
CC         STATE:  Ohio
CC         COUNTRY:  USA
CC         ZIP:  44114
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Floppy disk
CC         COMPUTER:  IBM PC compatible
CC         OPERATING SYSTEM:  PC-DOS/MS-DOS
CC         SOFTWARE:  PatentIn Release #1.0, Version #1.30
CC       CURRENT APPLICATION DATA:
```

```
CC         APPLICATION NUMBER:  US/08/224,632A
CC         FILING DATE:
CC         CLASSIFICATION:  530
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Golrick, Mary E.
CC         REGISTRATION NUMBER:  34,829
CC         REFERENCE/DOCKET NUMBER:  22727-00111
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  216 622 8458
CC         TELEFAX:  216 241 0816
CC     INFORMATION FOR SEQ ID NO:  4:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  15 amino acids
CC         TYPE:  amino acid
CC         STRANDEDNESS:
CC         TOPOLOGY:  linear
CC       MOLECULE TYPE:  peptide
CC       HYPOTHETICAL:  NO
SQ   SEQUENCE   15 AA; 1756 MW; 1288 CN;

  Query Match           29.1%;  Score 44;  DB 1;  Length 15;
  Best Local Similarity  62.5%;  Pred. No. 6.88e+02;
  Matches     5;  Conservative    2;  Mismatches   1;  Indels   0;  Gaps   0;

Db       6 QKGHRGTH 13
           :|||| :|
Qy      11 EKGHRPSH 18


RESULT   13
ID   US-07-882-923-7     STANDARD;     PRT;   20 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 7, Application US/07882923
XX
CC    Sequence 7, Application US/07882923
CC    Patent No. 5328899
CC     GENERAL INFORMATION:
CC       APPLICANT:  Boublik, Jaroslav H.
CC       APPLICANT:  Rivier, Jean E.F.
CC       APPLICANT:  Brown, Marvin R.
CC       APPLICANT:  Scott, Neal A.
CC       TITLE OF INVENTION:  NPY PEPTIDE ANALOGS
CC       NUMBER OF SEQUENCES:  14
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Fitch, Even, Tabin & Flannery
CC         STREET:  4250 Executive Square, Suite 510
CC         CITY:  La Jolla
CC         STATE:  CA
CC         COUNTRY:  USA
CC         ZIP:  92037
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Floppy disk
CC         COMPUTER:  IBM PC compatible
CC         OPERATING SYSTEM:  PC-DOS/MS-DOS
CC         SOFTWARE:  PatentIn Release #1.0, Version #1.25
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/07/882,923
CC         FILING DATE:  19920512
CC         CLASSIFICATION:  514
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 07/503,198
CC         FILING DATE:  30-MAR-1990
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  US 07/219,596
CC         FILING DATE:  15-JUL-1988
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Schumann, James J.
CC         REGISTRATION NUMBER:  20,856
CC         REFERENCE/DOCKET NUMBER:  52864
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  619-552-1311
CC         TELEFAX:  619-552-0095
CC     INFORMATION FOR SEQ ID NO:  7:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  20 amino acids
CC         TYPE:  AMINO ACID
CC         TOPOLOGY:  unknown
CC       MOLECULE TYPE:  peptide
SQ   SEQUENCE   20 AA; 2589 MW; 1767 CN;

  Query Match           29.1%;  Score 44;  DB 1;  Length 20;
  Best Local Similarity  30.8%;  Pred. No. 6.88e+02;
  Matches     4;  Conservative    6;  Mismatches   2;  Indels   1;  Gaps   1;

Db       7 ALRQYRNLITRQR 19
           :|| :: |: |::
Qy       1 SLRPFKALV-REK 12


RESULT   14
ID   US-08-329-151-28     STANDARD;     PRT;   15 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 28, Application US/08329151
XX
CC    Sequence 28, Application US/08329151
CC    Patent No. 5604203
CC     GENERAL INFORMATION:
CC       APPLICANT:  Balasubramaniam, A.
CC       TITLE OF INVENTION:  ANALOGS OF PEPTIDE YY AND USES
CC       TITLE OF INVENTION:  THEREOF
CC       NUMBER OF SEQUENCES:  30
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Fish & Richardson
CC         STREET:  225 Franklin Street
CC         CITY:  Boston
CC         STATE:  Massachusetts
CC         COUNTRY:  U.S.A.
CC         ZIP:  02110-2804
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
CC         COMPUTER:  IBM PS/2 Model 50Z or 55SX
CC         OPERATING SYSTEM:  MS-DOS (Version 5.0)
CC         SOFTWARE:  WordPerfect (Version 5.1)
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/329,151
CC         FILING DATE:
CC         CLASSIFICATION:  514
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  08/038,534
CC         FILING DATE:  3/29/93
CC         APPLICATION NUMBER:  08/109,326
CC         FILING DATE:  08/19/93
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Paul T. Clark
CC         REGISTRATION NUMBER:  30,162
CC         REFERENCE/DOCKET NUMBER:  00537/105001
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  (617) 542-5070
CC         TELEFAX:  (617) 542-8906
CC         TELEX:  200154
CC     INFORMATION FOR SEQ ID NO:  28:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  15
CC         TYPE:  amino acid
CC         STRANDEDNESS:  N/A
CC         TOPOLOGY:  linear
CC       FEATURE:
CC         OTHER INFORMATION:  Xaa in position 5 is an abbreviation of
```

```
CC         OTHER INFORMATION:  Thz.  The sequence has an acetylated N-terminus (i.e., N-
CC         OTHER INFORMATION:  amino N-terminus (i.e., H2N-).  The sequence has an amide
CC         OTHER INFORMATION:  CO-NH2), rather than a carboxyl C-terminus (i.e., CO-OH).
SQ   SEQUENCE   15 AA; 1847 MW; 1275 CN;

  Query Match           28.5%;  Score 43;  DB 1;  Length 15;
  Best Local Similarity  53.8%;  Pred. No. 8.50e+02;
  Matches     7;  Conservative    2;  Mismatches   3;  Indels   1;  Gaps   1;

Db      2 SLRXFLNLVTRQR 14
          ||| |  || |::
Qy      1 SLRPFKALV-REK 12


RESULT   15
ID   US-08-786-748A-66     STANDARD;     PRT;   21 AA.
XX
AC   xxxxxx
XX
DT
XX
DE   Sequence 66, Application US/08786748A
XX
CC    Sequence 66, Application US/08786748A
CC    Patent No. 5714577
CC     GENERAL INFORMATION:
CC       APPLICANT:  Ronald, Montelaro C.
CC       APPLICANT:  Tencza, Sarah B.
CC       APPLICANT:  Mietzner, Timothy A.
CC       TITLE OF INVENTION:  NOVEL ANTIMICROBIAL PEPTIDES
CC       NUMBER OF SEQUENCES:  169
CC       CORRESPONDENCE ADDRESS:
CC         ADDRESSEE:  Brumbaugh, Graves, Donohue & Raymond
CC         STREET:  30 Rockefeller Plaza
CC         CITY:  New York
CC         STATE:  New York
CC         COUNTRY:  USA
CC         ZIP:  10112-0228
CC       COMPUTER READABLE FORM:
CC         MEDIUM TYPE:  Diskette
CC         COMPUTER:  IBM Compatible
CC         OPERATING SYSTEM:  DOS
CC         SOFTWARE:  FastSEQ Version 2.0
CC       CURRENT APPLICATION DATA:
CC         APPLICATION NUMBER:  US/08/786,748A
CC         FILING DATE:  24-JAN-1997
CC         CLASSIFICATION:  514
CC       PRIOR APPLICATION DATA:
CC         APPLICATION NUMBER:  60/010,634
CC         FILING DATE:  26-JAN-1996
CC       ATTORNEY/AGENT INFORMATION:
CC         NAME:  Rochelle K. Seide
CC         REGISTRATION NUMBER:  32,300
CC         REFERENCE/DOCKET NUMBER:  AP30421
CC       TELECOMMUNICATION INFORMATION:
CC         TELEPHONE:  212-408-2500
CC         TELEFAX:  212-765-2519
CC     INFORMATION FOR SEQ ID NO:  66:
CC       SEQUENCE CHARACTERISTICS:
CC         LENGTH:  21 amino acids
CC         TYPE:  amino acid
CC         STRANDEDNESS:  single
CC         TOPOLOGY:  linear
CC       MOLECULE TYPE:  No. 5714577e
SQ   SEQUENCE   21 AA; 2527 MW; 1500 CN;

  Query Match           28.5%;  Score 43;  DB 1;  Length 21;
  Best Local Similarity  62.5%;  Pred. No. 8.50e+02;
  Matches     5;  Conservative    2;  Mismatches   1;  Indels   0;  Gaps   0;

Db      1 LIRELGQR 8
          |:|| |:|
Qy      8 LVREKGHR 15
```

Search completed: Tue Jun 22 15:01:25 1999
Job time : 41 secs.

****



****

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Jun 22 14:56:29 1999; MasPar time 4.30 Seconds
186.302 Million cell updates/sec

Tabular output not generated.

Title: >US-08-644-289-1
Description: (1-20) from US08644289.pep
Perfect Score: 151
Sequence: 1 SLRPFKALVREKGHRPSHSC 20

Scoring table: PAM 150
Gap 15

Searched: 122810 seqs, 40068593 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 30

Database: pir60
1:pir1 2:pir2 3:pir3 4:pir4

Statistics: Mean 28.488; Variance 40.935; scale 0.696

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description	Pred. No.

No matches found.

Search completed: Tue Jun 22 14:57:18 1999
Job time : 49 secs.

****

****

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Jun 22 14:57:36 1999; MasPar time 2.77 Seconds
203.787 Million cell updates/sec

Tabular output not generated.

Title: >US-08-644-289-1
Description: (1-20) from US08644289.pep
Perfect Score: 151
Sequence: 1 SLRPFKALVREKGHRPSHSC 20

Scoring table: PAM 150
Gap 15

Searched: 77977 seqs, 28268293 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 30

Database: swiss-prot37
1:swissprot

Statistics: Mean 29.227; Variance 35.378; scale 0.826

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description	Pred. No.

No matches found.

Search completed: Tue Jun 22 14:58:30 1999
Job time : 54 secs.

****

****

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Jun 22 14:58:48 1999; MasPar time 5.55 Seconds
196.656 Million cell updates/sec

Tabular output not generated.

Title: >US-08-644-289-1
Description: (1-20) from US08644289.pep
Perfect Score: 151
Sequence: 1 SLRPFKALVREKGHRPSHSC 20

Scoring table: PAM 150
Gap 15

Searched: 179066 seqs, 54579741 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 30

Database: sptrembl9
1:sp_archea 2:sp_bacteria 3:sp_fungi 4:sp_human
5:sp_invertebrate 6:sp_mammal 7:sp_mhc 8:sp_organelle
9:sp_phage 10:sp_plant 11:sp_rodent 12:sp_unclassified
13:sp_vertebrate 14:sp_virus

Statistics: Mean 28.060; Variance 36.106; scale 0.777

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description	Pred. No.

No matches found.

Search completed: Tue Jun 22 15:00:25 1999
Job time : 97 secs.